MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
äŒæ¥ã³ãŒãMXCT
äŒç€ŸåMaxCyte Inc
äžå Žæ¥Mar 29, 2016
æé«çµå¶è²¬ä»»è
ãCEOãMasoud (Maher)
åŸæ¥å¡æ°114
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Mar 29
æ¬ç€Ÿæåšå°9713 Key West Avenue,
éœåžROCKVILLE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·20850
é»è©±çªå·13015175556
ãŠã§ããµã€ãhttps://www.maxcyte.com/
äŒæ¥ã³ãŒãMXCT
äžå Žæ¥Mar 29, 2016
æé«çµå¶è²¬ä»»è
ãCEOãMasoud (Maher)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã